The SEMA6A antibody targets Semaphorin-6A (SEMA6A), a transmembrane protein belonging to the semaphorin family, which plays critical roles in axon guidance, neural circuit formation, and cell migration during development. SEMA6A interacts with plexin receptors to regulate cytoskeletal dynamics and signal transduction, influencing neuronal connectivity and tissue morphogenesis. In addition to its neurological functions, SEMA6A is implicated in cancer progression, immune regulation, and vascular development, with altered expression observed in glioblastoma, colorectal cancer, and other malignancies.
Anti-SEMA6A antibodies are widely used in research to study protein localization, expression levels, and functional mechanisms in both normal and pathological contexts. They enable techniques like immunohistochemistry, Western blotting, and flow cytometry, aiding in the exploration of SEMA6A's dual roles as a tumor suppressor or promoter, depending on cellular context. Commercial SEMA6A antibodies are typically validated for specificity against conserved domains, such as the Sema domain or cytoplasmic regions. Recent studies also highlight its potential as a therapeutic target or biomarker, driving interest in developing high-affinity antibodies for diagnostic and experimental applications. Researchers prioritize antibodies with minimal cross-reactivity to related semaphorins (e.g., SEMA6B or SEMA6D) to ensure accuracy in mechanistic studies.